Safety Study of TAK-700 in Subjects With Prostate Cancer.
The purpose of this study is to determine the safety and tolerability of TAK-700 in patients with asymptomatic metastatic, androgen independent prostate cancer.
Prostatic Neoplasms
DRUG: TAK-700
Safety and tolerability of TAK-700 by evaluating adverse events, vital signs, physical examination findings, concomitant medications and laboratory tests., Cycle 1: Weeks 1, 2, 3 and 4, then every 4 weeks thereafter.
Efficacy and pharmacokinetics (PSA response and/or objective disease response), Cycle 1: Weeks 1, 2, 3 and 4, then every 4 weeks thereafter.
The purpose of this study is to determine the safety and tolerability of TAK-700 in patients with asymptomatic metastatic, androgen independent prostate cancer.